51.63
+4.09%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Travere Therapeutics
From its filings with the US Securities and Exchange Commission
Travere Therapeutics is based in San Diego, California and is incorporated in California. Its shares trade on Nasdaq under the ticker TVTX. The SEC classifies its business as pharmaceutical preparations. In the fiscal year to 31 December 2025, it reported revenue of $490.7m and a net loss of $25.5m. At that date it held total assets of $605.2m and shareholders' equity of $114.8m.
We are a biopharmaceutical company headquartered in San Diego, California, focused on identifying, developing and delivering life-changing therapies to people living with rare kidney and metabolic diseases. Our approach centers on advancing our innovative pipeline with multiple late-stage clinical programs targeting rare diseases with significant unmet medical needs.
In September 2024, the U.S. Food and Drug Administration ("FDA") granted full approval to our lead development program, FILSPARI (sparsentan), which is indicated to slow kidney function decline in adults with primary Immunoglobulin A nephropathy ("IgAN") who are at risk of disease progression. IgAN is a rare progressive kidney disease and the most common type of primary glomerulonephritis worldwide. FILSPARI had previously been granted accelerated approval for IgAN in February 2023 based on the surrogate marker of proteinuria. Full approval was based on positive long-term confirmatory results from the PROTECT Study demonstrating that FILSPARI significantly slowed kidney function decline over two years compared to irbesartan.
Quoted from its 10-K, filed 19 Feb 2026. Read the filing on SEC.gov ↗
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 23 Jul 2003
- Employees
- 497
- Website
- retrophin.com ↗
- Head office
- 3611 VALLEY CENTRE DR, SAN DIEGO, CA, 92130
- Incorporated in
- CA
- Classification
- Pharmaceutical Preparations
- Filer status
- Large accelerated filer
Leadership
Pay as last reported
- Mr. Gary LyonsIndependent Chairman of the Board$262,320
- Dr. Eric DubePresident, Chief Executive Officer, Director, since 2019$5.2m
- Mr. Christopher ClineChief Financial Officer$1.5m
- Ms. Elizabeth ReedChief Legal Officer, General Counsel and Corporate Secretary$2.0m
- Mr. Peter HeermaChief Commercial Officer$1.5m
- Dr. Jula InrigChief Medical Officer$1.7m
- Dr. William RoteChief Research Officer$1.5m
- Dr. Roy BaynesIndependent Director$247,320
- Dr. Suzanne BruhnIndependent Director$242,320
- Mr. Timothy CoughlinIndependent Director$254,820
- Mr. Jeffrey MecklerIndependent Director$249,320
- Mr. John OrwinIndependent Director$242,320
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 93
- Environment
- 99
- Social
- 99
- Governance
- 82
- Carbon reduction policy
- No
- Human rights policy
- No
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Travere Therapeutics Inc has several strengths that contribute to its success. These include:
Weaknesses
- Despite its strengths, Travere Therapeutics Inc also has weaknesses that need to be addressed:
Opportunities
- Travere Therapeutics Inc has opportunities to further expand and improve its position in the market:
Threats
- However, there are also several threats that Travere Therapeutics Inc should be aware of and address:
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.